Epidemiology of chronic hepatitis C virus infection in high risk groups

Hepatitis Monthly

Volumn 8, Issue 1, 2008, Pages 11-16

  Christofidou, Myrto ^a   Jelastopulu, Eleni ^b   Economides, George ^a   Spillopoulou, Iris ^a   Siagris, Dimitris ^b   Labropoulou Karatza, Chryssoula ^b   Anastassiu, Evangelos D ^a   Dimitracopoulos, George ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

HCV epidemiology; HCV genotypes; Post transfusion hepatitis C

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; DIALYSIS; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; VIRAL CONTAMINATION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 44949231502     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispe-cies. Clin Liver Dis 1999; 3: 693-716.
2. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 122S-7S.
3. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C vi-rus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-9.
4. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, Follett EA, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amphfied from the 5′ non-coding region. J Gen Virol 1995; 76: 1197-204.
5. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-8.
6. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, et al. Geographical dis-tribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 884-92.
7. Pontisso P, Ruvoletto MG, Nicoletti M, Tisminetzky S, Gerotto M, Levrero M, et al. Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C. J Viral Hepat 1995; 2: 33-8.
8. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepa-titis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-9.
9. Driesel G, Wirth D, Stark K, Baumgarten R, Sucker U, Schreier E. Hepatitis C virus (HCV) genotype distribution in German isolates: studies on the sequence variability in the E2 and NS5 region. Arch Virol 1994; 139: 379-88.
10. Alonso Alonso P, Orduna A, San Miguel A, Dominguez E, Bratos MA, Gutierrez MP, et al. Relation of hepatitis C virus genotypes to risk factors and hepatic disease in Spanish pa-tients. Clin Microbiol Infect 1997; 3: 647-52.
11. Legler TJ, Riggert J, Simson G, Wolf C, Humpe A, Munzel U, et al. Testing of indi-vidual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion 2000; 40: 1192-7.
12. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet, 4000; 355: 887-91.
13. Saracco G, Sostegni R, Ghisetti V, Rocca G, Cariti G, Andreoni M, et al. Hepatitis C virus genotypes in a noncirrhotic Italian population with chronic hepatitis C: correlation with clinical, virological and histological parameters. Results of a prospective multicentre study. J Viral Hepat 2000; 7: 124-9.
14. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for ini-tial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
16. Fried MW, Sbiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
17. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Pegin-terferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
18. Ross RS, Viazov S, Kpakiwa SS, Roggendorf M. Transcription-mediated amplifica-tion linked to line probe assay as a routine tool for HCV typing in clinical laboratories. J Clin Lab Anal 2007; 21: 340-7.
19. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A pro-posed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
20. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-90.
21. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, et al. Re-lationsbip between hepatitis C virus genotypes and sources of infection in patients with chron-ic hepatitis C. J Infect Dis 1995; 171: 1607-10.
22. Christofidou M, Lambropoulou-Karatza C, Dimitracopoulos G, Spiliopoulou I. Distri-bution of hepatitis C virus genotypes in viremic patients with beta-thalassemia. Eur J Clin Microbiol Infect Dis 2000; 19: 728-30.
23. Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepi-demiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001; 65: 688-93.
24. Akbari A. Imanieh MH, Karimi M, Tabatabaee HR. Hepatitis C Virus Antibody Posi-tive Cases in Multitransfused Thalassemic Patients in South Iran. Hep Mon 2007; 7: 63-6.
25. Katsoulidou A, Paraskevis D, Kalapothaki V, Arvanitis D, Karayiannis P, Hadjicon-stantiou V, et al. Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Nephrol Dial Transplant 1999; 14: 1188-94.
26. Widell A, Christensson B, Wiebe T, Schalen C, Hansson HB, Allander T, et al. Epi-demiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediat-ric oncology service. Ann Intern Med 1999; 130: 130-4.
27. Zacks SL, Fried MW. Hepatitis B and C and renal failure. Infect Dis Clin North Am 2001; 15: 877-99.
28. Carneiro MA, Martins RM, Teles SA, Silva SA, Lopes CL, Cardoso DD, et al. Hepa-titis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Mem Ins Oswaldo Cruz 2001; 96: 765-9.
29. Siagris D, Labropoulou-Karatza C, Christofidou M, Goumenos D, Thomopoulos K, Lekkou A, et al. Viraemia, cryoglobulins and autoantibodies in haemodialysis patients in-fected with hepatitis C virus. Eur J Gastroenterol Hepatol 2003; 15: 133-7.
30. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, et al. Changing of hepatitis C virus gepotype patterns in France at the beginning of the third mil-lenium: The GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 405-13.
31. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999; 6: 435-43.
32. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implica-tions. Clin Liver Dis 2003; 7: 45-66.
33. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C vi-rus genotype 4 in the United States. J Clin Gastroenterol 2004; 38: 68-71.
34. Tamalet C, Colson P, Tissot-Dupont H, Henry M, Tourres C, Tivoli N, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol 2003; 71: 391-8.
35. Westin J, Lindh M, Lagging LM, Norkrans G, Wejstal R. Chronic hepatitis C in Swe-den: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999; 31: 355-8.
36. Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL. Viral evolution of hepati-tis C in injection drug users. J Viral Hepat 2005; 12: 574-83.
37. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
38. Sugimoto K, Kaplan DE, Ikeda F, Ding J, Schwartz J, Nunes FA, et al. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infec-tion. J Virol 2005; 79: 6976-83.
39. Okuda K, Hayashi H, Yokozeki K, Irie, Y. Destruction of hepatitis C virus particles by haemodialysis. Lancet 1996; 347: 909-10.
40. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit 2003; 9: RA19-22.
41. Grady RW, Akbar AN, Giardina PJ, Hilgartner MW, de Sousa M. Disproportionate lymphoid cell subsets in thalassaemia major: the relative contributions of transfusion and splenectomy. Br J Haematol 1985; 59: 713-24.
42. Rehermann B. Interaction between the hepatitis C virus and the immune system. Se-min Liver Dis 2000; 20: 127-41.